HistoSonics, Inc.
Classification
Private
Financials
Revenue & Profit
Valuation
Ratios
People
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
About
About
HistoSonics, Inc. is a privately-held firm that develops and manufactures a non-invasive and robotically assisted ultrasound therapy device designed for precise tissue destruction. HistoSonics, Inc. was founded in 2009 by Brian Fowlkes, Charles Cain, Hall Timothy, James Bertolina, M. Gibbons, Thomas Davison, William Robert, and Zhen Xu. HistoSonics, Inc. headquarters are located in Ann Arbor, Michigan.
Keywords
Keywords
Classified
Private
News
Loading...